Home | Welcome to Contract Pharma   
Last Updated Sunday, May 19 2013
Print

Industry News

Related Searches:

Filter by:

September 5, 2007
Medarex, Inc. and licensing partner, J&J subsidiary Centocor R&D, Inc., have extended their antibody development relationship, providing Centocor with continued access to Medarex's UltiMAb Human Antibody Development System for the generation…   Read More »
September 4, 2007
The first phase of Millipore Corp.'s plant modernization project is complete at its facility in Kankakee, IL. The plant manufactures certain key products including Probumin brand Bovine Serum Albumin and other products derived from bovine serum or pl…   Read More »
August 29, 2007
Catalent Pharma Solutions, Inc. and ALK-Abello A/S have signed an agreement that will expand Zydis production capacity dedicated to ALK-Abello's immunotherapy products. Under the agreement, ALK-Abello will fund a new production line for current and…   Read More »
August 29, 2007
PDL BioPharma, Inc., following a business and portfolio review, has changed its strategic focus to the discovery and development of novel antibodies in oncology and select immunological diseases. According to a company statement, it will realign its…   Read More »
August 29, 2007
BioReliance Corp. has launched iNet, an IT system that enables customers to submit test article details via controlled and secure Internet access from any location worldwide. Clients can view the status of current and past studies, view expected comp…   Read More »
August 28, 2007
Charles River Laboratories International has plans to build a new facility in Sherbrooke, Quebec, to support its preclinical services business. The new facility, which will be located in the company's newly constructed Sherbrooke Biomedical Park, wil…   Read More »
August 28, 2007
Pfizer has licensed non-exclusive, worldwide rights to Xoma Ltd.'s bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products. Under the terms of the agreement, Xoma will r…   Read More »
August 27, 2007
NovaQuest, the strategic partnering group of Quintiles Transnational, has made a strategic investment in Topigen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders.  The investment, part of a…   Read More »
August 24, 2007
Gene Logic, Inc. has entered into a drug repositioning and development agreement with Merck Serono to seek alternative development paths for several Merck Serono drug candidates that were discontinued or de-prioritized in clinical trials for reasons…   Read More »
August 24, 2007
MedImmune has opened a new, state-of-the-art pilot lab facility at its Gaithersburg site headquarters. The facility features the latest equipment and process automation systems and will support the company's clinical product pipeline with additional…   Read More »
August 23, 2007
Pro-Pharmaceuticals, Inc. has retained Camargo Pharmaceutical Services to provide strategic regulatory support for the company’s 505(b)(2) submissions for Davanat with the FDA. Camargo’s regulatory support includes the preparation and sub…   Read More »
August 23, 2007
Cephalon, Inc. has signed an agreement to acquire the North American rights to Amrix (cyclobenzaprine hydrochloride extended-release capsules) from ECR Pharmaceuticals for $100 million cash. ECR is eligible to receive future cash payments based on th…   Read More »
August 23, 2007
GPC Biotech AG is restructuring and will reduce its U.S. staff by 46 employees (approximately 15%) with reductions in the commercialization, drug development and general and administrative groups. The company also announced that Martine George, M.D.…   Read More »
August 22, 2007
Pfizer broke ground on a $50 million expansion at its Chesterfield campus that reflects the company's increased investment in biopharmaceuticals. The expansion doubles the size of a pilot plant that produces protein-based, injectable biologic drugs f…   Read More »
August 21, 2007
ImClone Systems, Inc. received approval from the FDA for a second facility to manufacture Erbitux. This new 250,000-sq.-ft. multi-suite manufacturing facility, referred to as "BB50", more than doubles the company's total production capacity…   Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On